STERIS Earnings Preview: What to Expect

Company Overview - STERIS plc, based in Mentor, Ohio, specializes in infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services, founded in 1985 [1] - The company's current market capitalization is $24.5 billion, with the Q3 2026 earnings report expected to be released soon [1] Earnings Expectations - Analysts predict STERIS will generate earnings of $2.53 per share for Q3 2026, reflecting a 9.1% increase from $2.32 per share in the same quarter last year [2] - For fiscal 2025, the expected EPS is $10.23, indicating an 11% increase from $9.22 reported in fiscal 2024, with further growth anticipated to $11.11 in fiscal 2027, an 8.6% year-over-year increase [3] Stock Performance - Over the past 52 weeks, STERIS shares have increased by 25.5%, outperforming the S&P 500 Index's 17.1% rise and the State Street Health Care Select Sector SPDR ETF's 14.3% return [4] - Following the release of its Q2 2026 earnings, STERIS shares closed up by 6.9%, with quarterly revenue reported at $1.5 billion, exceeding Wall Street estimates, and an adjusted EPS of $2.47 also surpassing projections [5] Analyst Ratings - The consensus view among analysts is moderately bullish, with a "Moderate Buy" rating overall; six out of nine analysts recommend a "Strong Buy," while three suggest a "Hold" [6] - The mean price target for STERIS is $288.86, indicating an 11.4% potential upside from current price levels [6]